> Disorders > Disease or Syndrome > Hydronephrosis

Hydronephrosis

Q: What is the most common cause of hydronephrosis?

The most common cause of hydronephrosis is an obstruction in the urinary tract, which can lead to the dilation and distension of the renal pelvis and calyces. This obstruction can be due to a variety of factors, such as kidney stones, tumors, or congenital abnormalities.

Q: Can hydronephrosis lead to kidney damage?

Yes, untreated hydronephrosis can lead to impaired kidney function and even kidney damage over time. This is because the obstruction and subsequent buildup of urine in the kidney can put pressure on the delicate kidney tissue, causing it to deteriorate.

Q: Are there different types of hydronephrosis?

Yes, there are different types of hydronephrosis based on the underlying cause. These include congenital hydronephrosis (present at birth), acquired hydronephrosis (developed later in life), and unilateral (affecting one kidney) or bilateral (affecting both kidneys) hydronephrosis.

Hydronephrosis is a condition characterized by the dilation and distension of the renal pelvis and calyces, often due to an obstruction in the urinary tract.
It can lead to impaired kidney function and even kidney damage if left untreated.
PubCompare.ai's AI-driven platform can help researchers optimize their hydronephrosis studies by efforlessly locating the best protocols and products from literature, pre-prints, and patents, allowing for accurate comparisons and enhanced reproducibility in their hydronephrosis research.

Most cited protocols related to «Hydronephrosis»

Serum Creatinine Reference Ranges in Healthy Children

In order to include measurements of children with normal serum creatinine level only, several steps of exclusion were carried out. Firstly, to prevent the influence of serial measurements, we randomly selected one assay per patient. Secondly, all determinations requested by the departments of Paediatric Nephrology, Paediatric Oncology and the Neonatal and Paediatric Intensive Care Units were excluded. Thirdly, the remaining patients were screened for pathophysiological conditions that could cause renal damage (Table 2).
Table 2

Exclusion criteria and the method of exclusion

Exclusion criterion	Method of exclusion	n^a
Kidney disease	Exclude all cases with kidney disease described in medical record	62
Use of cytostatic drugs	Exclude all patients receiving cytostatic drugs or with proven malignancy described in medical record	12
Premature	Exclude all patients with gestational age <37 weeks described in medical record	224
Small for gestational age	Exclude all cases if birth weight was: - <2300 g if gestational age = 37 weeks - <2500 g if gestational age = 38 weeks - <2700 g if gestational age = 39 weeks - <2900 g if gestational age = 40 weeks - <3000 g if gestational age = 41 weeks - < 3100 g if gestational age = 42 weeks	64
Muscle disease	Exclude all patients with muscle disease described in medical record	1
Haemolysis	Exclude all patients with proven haemolysis described in medical record or found in laboratory tests	0
Hyperbilirubinaemia	Exclude all patients with hyperbilirubinaemia proven with laboratory test	32
Hypertriglyceridaemia	Exclude all patients with hypertriglyceridaemia proven with laboratory test	2
Syndromes	Exclude all patients with a syndrome described in medical record. Exclude all patients with multiple congenital dysmorphisms described in medical record	79
After major surgery	Exclude all determinations performed after (cardio)thoracic surgery or extensive abdominal surgical procedure described in medical record	128
Prerenal problems	Exclude all patients with shock, dehydration, heart failure or cardiopulmonary resuscitation described in medical record	131
Urological problems	Exclude all patients with hydronephrosis, vesicoureteral reflux, urinary tract infection described in medical record	128

^aThe total number of exclusions is >748 because some patients were excluded for more than one reason

Patients born preterm (<37 weeks of gestational age) or small for gestational age (birth weight <10th percentile according to The Netherlands Perinatal Registry 2007 [13 ]) were excluded because of their expected immature renal function. All patients with a proven or suspected syndrome were also excluded, for many syndromes are associated with multiple organ anomalies, including renal pathology. Finally, during measurement on the Hitachi 912, those indices possibly associated with interference with the enzymatic method (hyperbilirubinaemia, hypertriglyceridaemia and haemolysis) were measured in each sample. Samples with indications of haemolysis, hyperbilirubinaemia or hypertriglyceridaemia were excluded. All patients with muscle disease were also excluded.
All assay results from 1- to 7-day-old children were included in view of the expected rapid initial decline in serum creatinine during the first days of life. For older children up to 3 months of age, 15 random determinations per week were included; for those between 3 and 12 months, five random determinations per week.
The exclusion procedure was carried out by two physicians who were blinded to the serum creatinine levels.

Boer D.P., de Rijke Y.B., Hop W.C., Cransberg K, & Dorresteijn E.M. (2010). Reference values for serum creatinine in children younger than 1 year of age. Pediatric Nephrology (Berlin, Germany), 25(10), 2107-2113.

Publication 2010

Abdomen Biological Assay Birth Weight Cardiopulmonary Resuscitation Child Childbirth Congestive Heart Failure Creatinine Cytostatic Agents Dehydration Enzymes Gestational Age Hemolysis Hydronephrosis Hyperbilirubinemia Hypertriglyceridemia Infant, Newborn Kidney Kidney Diseases Malignant Neoplasms MLL protein, human Multiple Abnormalities Myopathy Neoplasms Operative Surgical Procedures Patients Physicians Pregnancy Serum Shock Syndrome Thoracic Surgical Procedures Urinary Tract Infection Vesico-Ureteral Reflux

Comprehensive Evaluation of Percutaneous Nephrolithotomy

A total of 155 consecutive sPCNL cases were included from January 2004 through July 2012 at Seoul National University Bundang Hospital. Percutaneous renal access was routinely obtained by 2 experienced uro-radiologists 1 day before or on the operative day. If the patient previously had a percutaneous nephrostomy, this nephrostomy was used as an access. sPCNL was performed in a prone position by 1 of 4 faculty professors. A rigid nephroscope was used in combination with a ballistic lithotripter, stone forceps, and a suction tube. If needed, a flexible nephroscope and/or ureteroscope were also used for collecting systems that were inaccessible with a rigid nephroscope. In this setting, a Holmium laser and stone basket were used. Temporary drainage was usually maintained with a 14-F nephrostomy catheter.
All patients were evaluated with pre- and post-operative computed tomography (CT). The evaluated preoperative stone parameters included the number, largest diameter, total stone volume, renometry (complete, partial staghorn, or other), average Hounsfield units, and degree of hydronephrosis (normal, mild, moderate, or severe). A complete staghorn stone was defined as a renal pelvic calculi extending into all major calyceal groups filling at least 80% of the renal collecting system, and a partial staghorn stone was defined as a renal pelvic calculi extending into at least two calyceal groups. Stone volume was calculated by length×width×depth×π×0.52. The total stone volume was the sum of all stone volumes. The average Hounsfield unit was measured using the elliptical region of interest incorporated into the largest stone area in a non-contrast axial image [9] (link). “Stone-free” was defined as no evidence of residual stones on postoperative images for 1 month.

Jeong C.W., Jung J.W., Cha W.H., Lee B.K., Lee S., Jeong S.J., Hong S.K., Byun S.S, & Lee S.E. (2013). Seoul National University Renal Stone Complexity Score for Predicting Stone-Free Rate after Percutaneous Nephrolithotomy. PLoS ONE, 8(6), e65888.

Full text: Click here

Publication 2013

Calculi Catheters Drainage Faculty Forceps Hydronephrosis Kidney Kidney Calculi Muscle Rigidity Nephrostomy Patients Pelvis Pelvis, Renal Percutaneous Nephrostomies Radiologist Staghorn Calculi Suction Drainage Ureteroscopes X-Ray Computed Tomography YAG Laser, Ho

Assessing Internal Medicine Residents' POCUS Competence

To support the content development of our survey, key texts and articles on POCUS were reviewed [31 (link)–35 ]. An initial survey was drafted with input from two researchers (KW and IM) in July 2015, containing a list of 15 diagnostic applications, 10 procedures, and 80 basic knowledge items. For each survey item on diagnostic applications and procedures, two questions were asked: 1) How applicable is the application/procedure to patient care in internal medicine? 2) What is the participant’s skill in that area? For knowledge items, only self-reported level of knowledge was asked.
This survey was then piloted with 8 non-internal medicine residents in order to obtain input on survey length, content, and clarity. Based on feedback from the pilot data, in particular with respect to the length of the initial survey, we substantially revised the survey. For diagnostic applications, items on A-lines and Z-lines were removed, as they were felt to be too specific. The addition of two diagnostic applications was suggested: deep vein thrombosis and hydronephrosis. For procedures, incision and drainage was removed as the skills involved were felt to be redundant with the skills involved in abscess aspiration. Lastly, many of the 80 items on POCUS knowledge [26 (link)] were felt to be too specific, resulting in a survey that was unacceptably long. Ultimately, knowledge items were grouped into broader categories. The final survey included 15 diagnostic applications, 9 procedures, and 18 knowledge items, in addition to questions on baseline demographic data (see Additional file 1).
Using an online survey tool (SurveyMonkey Inc. San Mateo, California, USA; www.surveymonkey.com), the final survey was distributed to the trainees between April and June 2016. Up to two reminder emails were sent between two and 8 weeks to maximize participant response rate. As this study was unfunded, no incentives were used in this study at any study site.

Watson K., Lam A., Arishenkoff S., Halman S., Gibson N.E., Yu J., Myers K., Mintz M, & Ma I.W. (2018). Point of care ultrasound training for internal medicine: a Canadian multi-centre learner needs assessment study. BMC Medical Education, 18, 217.

Full text: Click here

Publication 2018

Abscess Deep Vein Thrombosis Diagnosis Drainage Feelings Hydronephrosis Self-Perception

Evaluating Glucocorticoid Response in IgG4-RD

A responder to therapy was defined as a patient who fulfilled one or more of the following items 4 weeks after initiation of the therapy: (1) improvement of organ function disorders such as decreased tear or salivary secretion, biliary obstruction and hydronephrosis; (2) the reduction of the target mass/organ’s diameter was >50% on physical examination, computed tomography (CT), magnetic resonance imaging (MRI) or ¹⁸F-fluorodeoxyglucose positron emission tomography CT (¹⁸F-FDG-PET-CT); or (3) the reduction of the target mass/organ’s diameter was >10% on physical examination, CT, MRI or ¹⁸F-FDG-PET-CT, and the reduction of serum IgG4 was >30%. If the patient has multiple organ involvements, he or she is regarded as a responder when the most prominent lesion fulfills the above criteria. Relapse of the disease was retrospectively determined when (1) any emerging or worsening of existing organ function disorders, organ swelling or mass-forming lesions were detected on physical examination, CT, MRI, or ¹⁸F-FDG-PET-CT and (2) the GC dose was increased or (3) an immunosuppressant was newly added to the GC regimen to control the emerging or worsening symptoms of IgG4-RD.
To evaluate the reduction speed of GC, we surveyed (a) the initial GC dose (mg), (b) the GC dose (mg) 3 months after initiation, (c) the GC dose (mg) 6 months after initiation, (d) the change at the first reduction from the initial GC dose (mg) and (e) the duration of the initial GC dose that was kept unchanged (days). Three parameters were defined as follows: (1) the rate of the reduction in the first 3 months: (a − b)/a, (2) the rate of the reduction in the first 6 months: (a − c)/a and (3) the speed of the reduction of the initial dose: d/e (mg/day).
The GC doses were converted to equivalent PSL doses.

Shirakashi M., Yoshifuji H., Kodama Y., Chiba T., Yamamoto M., Takahashi H., Uchida K., Okazaki K., Ito T., Kawa S., Yamada K., Kawano M., Hirata S., Tanaka Y., Moriyama M., Nakamura S., Kamisawa T., Matsui S., Tsuboi H., Sumida T., Shibata M., Goto H., Sato Y., Yoshino T, & Mimori T. (2018). Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Scientific Reports, 8, 10262.

Full text: Click here

Publication 2018

Cholestasis Drug Tapering F18, Fluorodeoxyglucose Hydronephrosis IgG4 Immunoglobulin G4-Related Disease Immunosuppressive Agents Patients Physical Examination Relapse Salivation Scan, CT PET Serum Tears Therapeutics Treatment Protocols X-Ray Computed Tomography

Longitudinal Kidney Volume and Function in ADPKD

All patients fulfilled Ravine’s diagnostic criteria of ADPKD. One hundred and eighty-eight patients with ADPKD gave informed consent to take part in an observational clinical study protocol measuring TKV once a year with simultaneous collection of 24-h urine for determination of creatinine clearance (Ccr) and urinary protein excretion between April 2007 and July 2012. Patients with end-stage renal disease (ESRD) underwent TKV measurement only. Of 188 patients, 70 underwent TKV measurement three times or more. Two patients who received laparoscopic cyst fenestration, one patient with a ureteral stone with hydronephrosis during the study period, and three patients with baseline ESRD were excluded from analysis.
Serum creatinine was measured enzymatically. Kidney function was estimated with Ccr using 24-h urine, reciprocal creatinine and eGFR. eGFR was calculated using the following formula—eGFR (male) = 194 × Cr^−1.094 × Age^−0.287, and eGFR (female) = eGFR (male) × 0.739. This equation is a Japanese coefficient of the modified Isotope Dilution Mass Spectrometry−Modification of Diet in Renal Disease (IDMS–MDRD) Study [11 (link)]. The staging of kidney function is based on the Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for CKD [12 (link)] using the final eGFR measurement.
TKV was measured by high-resolution magnetic resonance imaging (MRI) using a volumetric measurement of cross-sectional imaging, as described in the report from the CRISP study [13 (link)]. Gadolinium enhancement was not used for safety reasons. TKV was adjusted by height (ht-TKV, ml/m), body surface area (bs-TKV, ml/m²) and log-converted form (log-TKV, log[ml]). Kidney volume was measured by one radiologist (KK). Intrareader reliability was extremely high—the correlation coefficient was 0.999 for ten different single kidney volume measurements at different times when blind to first measurement. The mean of the % difference between two measurements was 0.29 ± 3.28 (SD) %.
Twenty-four-hour urinary protein excretion was expressed as the mean value of several measurements for each patient. The slopes of TKV, adjusted TKV parameters and kidney function parameters were calculated using linear regression analysis for each patient. %TKV was calculated with baseline TKV as 100 %.
The study protocol was approved by an institutional review board (09-56), and the study was conducted in accordance with the guidelines of the Declaration of Helsinki. All participants gave written informed consent to use their clinical data for medical research.

Higashihara E., Nutahara K., Okegawa T., Shishido T., Tanbo M., Kobayasi K, & Nitadori T. (2013). Kidney volume and function in autosomal dominant polycystic kidney disease. Clinical and Experimental Nephrology, 18(1), 157-165.

Publication 2013

ANP32B protein, human Blindness Body Surface Area Creatinine Cyst Diagnosis Dietary Modification EGFR protein, human Ethics Committees, Research Gadolinium Hydronephrosis Isotopes Japanese Kidney Kidney Diseases Kidney Failure, Chronic Labyrinth Fenestration Laparoscopy Males Mass Spectrometry Patients Polycystic Kidney, Autosomal Dominant Proteins Radiologist Renal Agenesis, Unilateral Safety Serum Technique, Dilution Ureterolithiasis Urine Urine Specimen Collection Woman

Most recents protocols related to «Hydronephrosis»

Nationwide UTUC Cohort Protocol

From March 01, 2001 to March 31, 2021, a total of 4016 patients with UTUC who undergo NU as the primary surgery were enrolled from the Taiwan UTUC Collaboration Group registry database for analysis. Patients with missing data on any of the variables for analysis were excluded (n = 2787). Patients younger than 18 years (n = 5), with end-stage renal disease prior to surgery (n = 156), who received kidney transplantation (n = 16), or had undergone NU previously (n = 10) were excluded. Patients who had received neoadjuvant chemotherapy (NAC) prior to surgery (n = 23) or who underwent bilateral NU simultaneously (n = 1) were also excluded from the study (Supplementary Figure S1).
Demographic data, including age, sex, comorbidities (hypertension, diabetes mellitus, or coronary artery disease), tumor site (right or left), location (renal pelvis only or ureter involvement), ipsilateral hydronephrosis (presence or absence), tumor focality (single or multiple), and tumor size, were collected. Ipsilateral hydronephrosis was defined as the hydronephrosis presenting on the same side as tumor involvement. Pathological tumor staging was recorded according to the eighth edition of the American Joint Committee on Cancer Staging Manual. Post-NU events such as sepsis or shock were also recorded (Table 1).

Cheng P.Y., Lee H.Y., Li W.M., Huang S.K., Liu C.L., Chen I.H., Lin J.T., Lo C.W., Yu C.C., Wang S.S., Chen C.S., Tseng J.S., Lin W.R., Yeong-Chin J., Cheong I.S., Jiang Y.H., Lee Y.K., Chen Y.T., Chen S.H., Chiang B.J., Hsueh T.Y., Huang C.Y., Wu C.C., Lin W.Y., Tsai Y.C., Yu K.J., Huang C.P., Huang Y.Y, & Tsai C.Y. (2023). Preoperative hydronephrosis is an independent protective factor of renal function decline after nephroureterectomy for upper tract urothelial carcinoma. Frontiers in Oncology, 13, 944321.

Full text: Click here

Publication 2023

Coronary Artery Disease Diabetes Mellitus High Blood Pressures Hydronephrosis Joints Kidney Failure, Chronic Kidney Transplantation Malignant Neoplasms Neoadjuvant Chemotherapy Neoplasms Operative Surgical Procedures Patients Pelvis, Renal Septicemia Shock Ureter Youth

Pediatric Kidney Screening Protocol

All children of 7 to 15 years who came to the hospital pediatrics departments
during study periods for a follow-up examination for mildly treated conditions
or examined because of problems unrelated to the kidneys or for a routine
check-up were included in the study. Children with any clinical evidence of
kidney disease were excluded from the study. Any abnormal sonographic findings
of kidney-like parenchymal mass lesions and hydronephrosis were excluded from
the study. In total, 403 children who fulfilled the inclusion criteria were
included in the study.

Tsehay B, & Seyoum G. (2023). Sonographic Evaluation of the Morphology of Kidneys Among Apparently Healthy Children in Northwest Ethiopia, 2021: The Normal Limits and Percentile Curves. Canadian Journal of Kidney Health and Disease, 10, 20543581231158071.

Publication 2023

Child Hydronephrosis Kidney Ultrasonography

Comparison of Ultrasound and Fluoroscopy in PCNL

The initial screening of studies was carried out by two reviewers independently based on titles and abstracts to exclude non-related studies. The full text of related studies was then reviewed for confirmation of eligibility criteria meeting and data extraction. The data extraction of each study using an Excel-based sheet were checked and discussed by two reviewers independently. The data sheet included the first author names, type of studies, year of publications, number of patients in ultrasound and fluoroscopy group, patients’ characteristics, SFRs, PCNL techniques, multiple stone status, stone burden, hydronephrosis degree, ultrasound probe, sheath size, dilator, complication rate, surgery time and Hb decrease after the surgery. The methodological quality of the included studies was independently assessed by two reviewers using the national institute of health (NIH) quality assessment tool for cohort studies [13 ] and the risk of bias (RoB2) method of the Cochrane Collaboration for RCTs [14 (link)].

Arabzadeh Bahri R., Maleki S., Shafiee A, & Shobeiri P. (2023). Ultrasound versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy: A systematic review and meta-analysis. PLOS ONE, 18(3), e0276708.

Full text: Click here

Publication 2023

Calculi Eligibility Determination Fluoroscopy Hydronephrosis Operative Surgical Procedures Patients Ultrasonography

Urinary Stone Treatment Outcomes

Age, gender, and body mass index (BMI) of the patient; comorbidities (hypertension, diabetes, and coronary heart disease); prior history of urinary stones; characteristics of the stones (stone side, location, size, Hounsfield unit of the stone, skin-to-stone distance (SSD), and grade of hydronephrosis); and complications (including febrile urinary tract infection [UTI], sepsis, steinstrasse, renal colic need analgesic requirement, and renal hematoma) were recorded.
A stone between the pelvic-ureteric junction and the upper border of the sacro-iliac junction was referred to as a proximal ureteral stone. A middle ureteric stone was described as one that was between the upper and lower borders of the sacro-iliac junction (iliac vessel crossing). A stone between the lower edge of the sacro-iliac junction and the bladder’s ureter opening is referred to as a distal ureteral stone. The stone’s biggest diameter, as determined by computed tomography, was used to estimate its size (CT). When SWL was taking place, a real-time ultrasound monitor monitored the skin-to-stone distance (SSD). Using a CT scan, the degree of hydronephrosis was determined and graded from 0 to 4. Grade 0 kidneys were those without either calix or pelvic dilation; grade 1 kidneys had only pelvic dilation; grade 2 kidneys had mild calix dilation alongside; grade 3 kidneys had severe calix dilation; and grade 4 kidneys had calix dilation along with renal parenchyma atrophy. Hounsfield units were used to measure the CT attenuation value (the stone in the maximal diameter, where the elliptical region of interest incorporated the largest cross-sectional area of stone without including adjacent soft tissue).
Data on complications were classified according to the Clavien–Dindo classification [12 (link)], with Clavien II and above indicating major morbidity. Renal colic was defined as the patients who reported colic and who needed analgesic (opioids or nonsteroidal anti-inflammatory drugs) to control it. Steinstrasse were confirmed by KUB or CT after SWL, either requiring intervention or not (such as SWL retreatment, double J placement, and so on). A febrile urinary tract infection (fUTI) was defined as a body temperature higher than 38 ℃ with pyuria or bacteriuria [13 (link)]. Sepsis was defined based on the criteria set by the sepsis definitions conference [14 (link)]. Follow-up visits were performed at one month after SWL, to see if there were any complications.

Na L., Li J., Pan C., Zhan Y, & Bai S. (2023). Development and validation of a predictive model for major complications after extracorporeal shockwave lithotripsy in patients with ureteral stones: based on a large prospective cohort. Urolithiasis, 51(1), 42.

Publication 2023

Analgesics Anti-Inflammatory Agents, Non-Steroidal Atrophy Blood Vessel Body Temperature Calculi Conferences Diabetes Mellitus Fever Gender Heart Disease, Coronary Hematoma High Blood Pressures Hydronephrosis Ilium Index, Body Mass Kidney Kidney Calices Opioids Pathological Dilatation Patients Pelvis Renal Colic Retreatments Septicemia Skin Tissues Ultrasonography Ureter Ureterolithiasis Urinary Bladder Urinary Calculi Urinary Tract Infection X-Ray Computed Tomography

Chemopreventive Efficacy of Kawain in UPII-mutant Ha-ras Mice

Cohorts of UPII-mutant Ha-ras mice were generated as described previously [6 (link),7 (link),8 (link)] and were provided (a) control diet (AIN93M diet) and (b) 0.6% kawain [0.6% kawain (w/w) in AIN-93M diet] (Dyets, Inc., Bethlehem, PA, USA) [8 (link)]. Each group contained 18 mice. These treatments started at four weeks of age and allow a one-week equilibration period after weaning. Comparable initial body weight was achieved in each group through a randomization process. Groups of survived mice were terminated at six months of age by CO₂ asphyxiation. We have recorded: (1) body weight and food consumption weekly, (2) time to death or sacrifice, (3) organ weight (heart, lung, liver prostate thymus, kidney, etc.) at the end of the experiment, (4) tumor burden (bladder and ureteral weight), (5) pathological changes: simple hyperplasia, nodular hyperplasia, and low-grade papillary carcinoma, and (6) obstructive uropathy [6 (link),7 (link),8 (link)]. The chemopreventive efficacies were comprehensively analyzed by comparing bladder and ureteral weight, survival time, pathological grade, incidence of hydronephrosis, and time to hematuria to the control groups. The approved protocol by UCI was followed (protocol #:2004-2540) for animal care and all experimental procedures.

Liu Z., Song L., Xie J., Wu X.R., Gin G.E., Wang B., Uchio E, & Zi X. (2023). Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism. Molecules, 28(4), 1666.

Full text: Click here

Publication 2023

Animals Asphyxia Carcinoma, Papillary Diet Food Heart Hematuria HRAS protein, human Hydronephrosis Hyperplasia kavain Kidney Liver Lung Mus Prostate Thymus Plant Tumor Burden Ureter Urinary Bladder Urologic Diseases

Top products related to «Hydronephrosis»

Sas statistical software by SAS Institute

Sourced in United States, Austria, Japan, Cameroon

SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.

Flex x2 by Storz

Sourced in Germany

The Flex X2 is a versatile laboratory equipment designed for a range of scientific applications. It features a compact and durable construction, providing a reliable tool for various research and testing purposes. The core function of the Flex X2 is to facilitate precise measurements and data collection within the laboratory environment.

Spss software version 22 by IBM

Sourced in United States, Japan, Belgium, United Kingdom, Germany

SPSS software version 22.0 is a comprehensive statistical analysis tool designed to handle a wide range of data types and perform advanced analytical tasks. The software provides a user-friendly interface and a robust set of statistical procedures, enabling researchers, analysts, and professionals to effectively analyze and interpret data.

Spss ver 17 by IBM

Sourced in United States, Japan

SPSS (Statistical Package for the Social Sciences) version 17.0 is a software application primarily used for statistical analysis. It provides a comprehensive set of tools for data management, data analysis, and reporting. The software is designed to handle a wide range of data types and offers a variety of statistical techniques, including descriptive statistics, regression analysis, and multivariate analysis.

Sas version 9 by SAS Institute

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India

SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

Acuson s2000 by Siemens

Sourced in Germany, United States, France, Japan

The Acuson S2000 is a diagnostic ultrasound system developed by Siemens. It is designed for general imaging applications, providing high-quality imaging capabilities.

Aquilion one by Toshiba

Sourced in Japan, Germany, United States

The Aquilion ONE is a computed tomography (CT) scanner developed by Toshiba. It is capable of performing whole-body scans in a single rotation, allowing for faster and more comprehensive imaging. The Aquilion ONE utilizes advanced technology to capture high-quality images, but a detailed description of its core function is not available without extrapolation or interpretation.

Spss ver 19 by IBM

Sourced in United States

SPSS version 19.0 is a statistical analysis software package developed by IBM. It provides tools for data management, analysis, and presentation. The software is designed to handle a wide range of data types and offers a variety of statistical techniques, including regression analysis, factor analysis, and hypothesis testing.

Spss software by IBM

Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, China, Italy, India, Israel, France, Spain, Denmark, Canada, Hong Kong, Poland, Australia

SPSS is a software package used for statistical analysis. It provides a graphical user interface for data manipulation, statistical analysis, and visualization. SPSS offers a wide range of statistical techniques, including regression analysis, factor analysis, and time series analysis.

Rat guillotine by Harvard Bioscience

Sourced in United States

The Rat Guillotine is a precision instrument designed for the humane euthanasia of laboratory rats. It provides a quick and painless method for animal sacrifice that complies with ethical standards for scientific research.

What is the most common cause of hydronephrosis?

Can hydronephrosis lead to kidney damage?

Are there different types of hydronephrosis?

How can PubCompare.ai help with hydronephrosis research?

PubCompare.ai's AI-driven platform can help researchers optimize their hydronephrosis studies by efforlessly locating the best protocols and products from literaturre, pre-prints, and patents. This allows for accurate comparisons and enhanced reproducibility in their hydronephrosis research, ensuring they can identify the most effective approaches for their specific goals.

What are some common applications of hydronephrosis research?

Hydronephrosis research is important for understanding the underlying causes, diagnostic methods, and treatment options for this condition. This can lead to improvements in patient care, such as earlier detection, more effective therapies, and better management of kidney health. Researchers may also explore the use of novel technologies or therapies to address hydronephrosis and its related complications.

More about "Hydronephrosis"

Hydronephrosis is a medical condition characterized by the dilation and distension of the renal pelvis and calyces, often due to an obstruction in the urinary tract.
This condition can lead to impaired kidney function and even kidney damage if left untreated.
Researchers studying hydronephrosis can utilize various statistical software and imaging technologies to optimize their research.
SAS statistical software, SPSS software (versions 17.0, 19.0, and 22.0), and Flex X2 can be employed for data analysis and reporting.
Imaging modalities such as the Acuson S2000, Aquilion ONE, and Rat guillotine can be used to visualize and assess the degree of hydronephrosis.
PubCompare.ai's AI-driven platform can be a valuable tool for researchers working on hydronephrosis.
The platform allows users to effortlessly locate the best protocols and products from literature, pre-prints, and patents, enabling accurate comparisons and enhanced reproducibility in their hydronephrosis research.
This can help researchers optimize their studies and drive advancements in the understanding and treatment of this condition.
Key subtopics related to hydronephrosis include the causes (e.g., urinary tract obstruction), symptoms (e.g., flank pain, recurrent urinary tract infections), diagnosis (e.g., imaging techniques, urodynamic studies), and management (e.g., conservative treatment, surgical intervention).
Researchers may also investigate the relationship between hydronephrosis and other urological conditions, such as vesicoureteral reflux and ureteropelvic junction obstruction.
By leveraging the insights and tools available, researchers can enhance the efficiency and effectiveness of their hydronephrosis studies, ultimately contributing to the advancement of our understanding and treatment of this medical condition.